|
Market Closed -
Other stock markets
|
After hours 01:00:00 | |||
| 485.39 USD | -2.24% |
|
482.70 | -0.55% |
| 07-09 | RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $577 From $570 | MT |
| 07-08 | Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 554.56 | +14.25% | 25 | ||||||
| 1,243.43 | +4.61% | 28 | ||||||
| 259 | +0.79% | 22 | ||||||
| 261.68 | +5.48% | 28 | ||||||
| 359.22 | +6.72% | 18 | ||||||
| 153.66 | -0.25% | 21 | ||||||
| 215.33 | +25.02% | 22 | ||||||
| 316.91 | -1.66% | 24 | ||||||
| 355.66 | -2.13% | 29 | ||||||
| 158.3 | +21.93% | 27 | ||||||
| 28.94 | +19.74% | 26 | ||||||
| 62.96 | +9.34% | 24 | ||||||
| 96.31 | +26.35% | 23 | ||||||
| 21.2 | +8.08% | 19 | ||||||
| 10,006.67 | +35.43% | 15 | ||||||
| 54.28 | +8.3% | 16 | ||||||
| 80.92 | +45.15% | 15 | ||||||
| 6,106.87 | +13.96% | 15 | ||||||
| 4.142 | +14.49% | 17 | ||||||
| 440.75 | +47.53% | 24 | ||||||
| Average | 1,039.04 | +15.16% | 22 | ||||||
| Weighted average by Cap. | 706.74 | +8.34% | 24 |
- Stock Market
- Stocks
- VRTX Stock
- Sector Vertex Pharmaceuticals Incorporated
- Sector consensus
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
